Following Win Over Boston Scientific, Medinol Seeks Taxus Liberté Royalties
This article was originally published in The Gray Sheet
Executive Summary
Medinol says it will pursue royalties from sales of Boston Scientific's Taxus Liberté drug-eluting stent following a Sept. 21 settlement of the firms' long-running patent infringement suit